| Literature DB >> 23418574 |
Meng Wu1, Ziwen Wang, Chuisong Meng, Kailiang Wang, Yanna Hu, Lizhong Wang, Qingmin Wang.
Abstract
A series of trans-3-aryl acrylic acids 1-27 and their derivatives 28-34 were prepared and evaluated for their antiviral activity against tobacco mosaic virus (TMV) for the first time. The bioassay results showed that most of these compounds exhibited good antiviral activity against TMV, of which compounds 1, 5, 6, 20, 27 and 34 exhibited significantly higher activity against TMV than commercial Ribavirin both in vitro and in vivo. Furthermore, these compounds have more simple structure than commercial Ribavirin, and can be synthesized more efficiently. These new findings demonstrate that trans-3-aryl acrylic acids and their derivatives represent a new template for antiviral studies and could be considered for novel therapy against plant virus infection.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23418574 PMCID: PMC3572066 DOI: 10.1371/journal.pone.0056475
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Chemical structure of Ribavirin, acrylic acids 1–3 and acid 29.
Figure 2Synthesis of trans-3-(substitutedphenyl)acrylic acids (4–11).
Figure 3Synthesis of trans-3-aryl acrylic acids (12–26).
Figure 4Synthesis of 6-benzyloxy-2,3-dimethoxyphenanthren-9-carboxaldehyde (36m).
Figure 5Synthesis of 2,3-dimethoxy6-hydroxyl-phenanthren-9-carboxaldehyde (36n) and 6,7-dimethoxy3-hydroxyl-phenanthren-9-carboxaldehyde (36o).
Figure 6Synthesis of trans-3-(2-hydroxyl-1-naphthyl)acrylic acid (27).
Figure 7Synthesis of compound 28.
Figure 8Synthesis of trans-3-aryl methylacrylate 30–34.
In Vitro and In Vivo Anti-TMV Activity of Compounds 1–34 at 500 µg/mL.
| Compd. |
|
| ||
| Inactivation effect (%)a | Curative effect (%)a | Protection effect (%)a | ||
|
|
|
|
|
|
|
| 16.5 | 20.8 | 3.9 | 12.0 |
|
| 33.4 | 48.4 | 3.3 | 10.1 |
|
| 28.7 | 45.6 | 12.6 | 22.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 29.1 | 15.1 | 24.3 | 8.9 |
|
| 20.6 | 10.4 | 10.3 | 11.6 |
|
| 26.9 | 27.0 | 10.9 | 14.7 |
|
| 20.4 | 23.8 | 23.8 | 8.3 |
|
| 25.3 | 14.8 | 15.4 | 6.0 |
|
| 26.8 | 20.7 | 22.1 | 28.4 |
|
| 30.0 | 22.9 | 21.4 | 19.3 |
|
| 27.5 | 23.4 | 16.8 | 20.2 |
|
| 0 | 0 | 0 | 8.3 |
|
| 18.5 | 11.1 | 10.3 | 17.2 |
|
| 21.3 | 19.2 | 15.2 | 18.6 |
|
| 17.5 | 21.9 | 19.3 | 20.4 |
|
| 20.0 | 13.7 | 10.2 | 15.2 |
|
|
|
|
|
|
|
| 22.3 | 17.1 | 17.5 | 21.4 |
|
| 36.7 | 30.1 | 33.3 | 40.2 |
|
| 34.4 | 21.0 | 25.3 | 30.7 |
|
| 42.8 | 31.3 | 37.9 | 34.4 |
|
| 38.3 | 31.6 | 30.0 | 28.8 |
|
| 34.4 | 21.0 | 25.3 | 30.7 |
|
|
|
|
|
|
|
| 27.2 | 20.8 | 38.7 | 12.5 |
|
| 27.1 | 11.4 | 10.8 | 6.1 |
|
| 23.8 | 20.0 | 20.6 | 17.3 |
|
| 37.5 | 30.0 | 33.3 | 32.8 |
|
| 31.7 | 28.9 | 27.2 | 35.4 |
|
| 37.6 | 33.3 | 24.6 | 31.8 |
|
|
|
|
|
|
|
|
|
|
|
|
(a: For details please see Supporting Information: Text S1).